Dalvance

Active Ingredient(s): Dalbavancin Hydrochloride
FDA Approved: * May 23, 2014
Pharm Company: * DURATA THERAPEUTICS
Category: Antibiotics

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Dalvance Overview

Dalbavancin (INN, trade names Dalvance in the US and Xydalba in Europe) is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).[2] Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin.[...

Read more Dalvance Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dalbavancin

Recent Dalvance Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dalbavancin Hydrochloride
  • Injection: 500mg/vial
  • Powder: 500mg/vial
  • Powder, Lyophilized: 500mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Dalvance: (1 result)

Sorted by National Drug Code
  • 57970-100 Dalvance 500 mg/25ml Intravenous Injection, Powder, for Solution by Durata Therapeutics Inc.

Other drugs which contain Dalbavancin Hydrochloride or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 25 April 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA